ES3029608T1 - Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5 - Google Patents
Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5 Download PDFInfo
- Publication number
- ES3029608T1 ES3029608T1 ES20811359T ES20811359T ES3029608T1 ES 3029608 T1 ES3029608 T1 ES 3029608T1 ES 20811359 T ES20811359 T ES 20811359T ES 20811359 T ES20811359 T ES 20811359T ES 3029608 T1 ES3029608 T1 ES 3029608T1
- Authority
- ES
- Spain
- Prior art keywords
- quinolin
- pyrazol
- acetamide
- pyridin
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19383057 | 2019-11-28 | ||
| PCT/EP2020/083566 WO2021105317A1 (en) | 2019-11-28 | 2020-11-27 | Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3029608T1 true ES3029608T1 (en) | 2025-06-24 |
Family
ID=68808255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES20811359T Pending ES3029608T1 (en) | 2019-11-28 | 2020-11-27 | Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5 |
Country Status (15)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3978487A1 (en) | 2020-09-30 | 2022-04-06 | Origo Biopharma, S.L. | 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5 |
| AU2025225502A1 (en) | 2024-02-22 | 2026-07-30 | Agomab Spain S.L.U. | Crystalline phase forms of a benzylamide derivative |
| WO2026082960A1 (en) | 2024-10-18 | 2026-04-23 | Agomab Therapeutics Nv | 1,5-naphtyridine and quinoline based inhibitors of alk5 |
| WO2026082968A1 (en) | 2024-10-18 | 2026-04-23 | Agomab Therapeutics Nv | Novel compounds |
| CN122036718A (zh) * | 2026-01-30 | 2026-05-15 | 安炎达医药技术(广州)有限公司 | 一种alk5抑制剂及其制备方法和应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3621540A1 (de) | 1986-06-27 | 1988-01-07 | Basf Ag | Chinolinderivate, verfahren zu ihrer herstellung, diese enthaltende mikrobizide und ihre verwendung zur bekaempfung von bakterien und pilzen |
| ATE291020T1 (de) * | 2001-02-02 | 2005-04-15 | Smithkline Beecham Corp | Pyrazolderivate gegen tgf überexprimierung |
| WO2004026306A2 (en) | 2002-09-18 | 2004-04-01 | Pfizer Products Inc. | Pyrazole derivatives as transforming growth factor (tgf) inhibitors |
| WO2004026302A1 (en) * | 2002-09-19 | 2004-04-01 | Eli Lilly And Company | Methods of inhibiting tgf beta with substituted pyrazoles |
| CL2004000234A1 (es) * | 2003-02-12 | 2005-04-15 | Biogen Idec Inc | Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid |
| CN102056907B (zh) | 2008-04-04 | 2014-12-31 | 武田药品工业株式会社 | 杂环衍生物及其用途 |
| US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| WO2011076725A1 (en) | 2009-12-21 | 2011-06-30 | Bayer Cropscience Ag | Thienylpyri (mi) dinylazole and their use for controlling phytopathogenic fungi |
| RU2612958C2 (ru) * | 2011-07-13 | 2017-03-14 | Ск Кемикалз Ко., Лтд. | 2-пиридилзамещенные имидазолы в качестве ингибиторов alk5 и/или alk4 |
| US11021468B2 (en) * | 2015-04-01 | 2021-06-01 | Rigel Pharmaceuticals, Inc. | TGF-ß inhibitors |
| WO2016172631A2 (en) | 2015-04-24 | 2016-10-27 | President And Fellows Of Harvard College | Substrate selective inhibitors of insulin-degrading enzyme (ide) and uses thereof |
| KR102434226B1 (ko) * | 2016-06-30 | 2022-08-19 | 한미약품 주식회사 | Alk5 억제제로서의 신규 피라졸 유도체 및 이의 용도 |
| JP2021518855A (ja) | 2018-03-02 | 2021-08-05 | ユニヴェルシテ ド ローザンヌ | Ｗｎｔシグナル伝達経路阻害剤としてのピラゾール誘導体 |
| US11945803B2 (en) | 2018-08-07 | 2024-04-02 | Tosk, Inc. | Modulators of RAS GTPase |
| CN110433164A (zh) * | 2019-08-15 | 2019-11-12 | 南开大学 | TGF-beta受体分子抑制剂在治疗小鼠动物模型中急性髓系白血病的应用 |
| EP3978487A1 (en) | 2020-09-30 | 2022-04-06 | Origo Biopharma, S.L. | 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5 |
-
2020
- 2020-11-27 BR BR112022010251A patent/BR112022010251A2/pt unknown
- 2020-11-27 AR ARP200103298A patent/AR120578A1/es unknown
- 2020-11-27 IL IL293388A patent/IL293388B2/en unknown
- 2020-11-27 PH PH1/2022/551177A patent/PH12022551177A1/en unknown
- 2020-11-27 CA CA3160963A patent/CA3160963A1/en active Pending
- 2020-11-27 MX MX2022005843A patent/MX2022005843A/es unknown
- 2020-11-27 AU AU2020394531A patent/AU2020394531B2/en active Active
- 2020-11-27 WO PCT/EP2020/083566 patent/WO2021105317A1/en not_active Ceased
- 2020-11-27 CN CN202080080848.3A patent/CN114787145B/zh active Active
- 2020-11-27 EP EP20811359.7A patent/EP4065572A1/en active Pending
- 2020-11-27 ES ES20811359T patent/ES3029608T1/es active Pending
- 2020-11-27 US US17/780,099 patent/US12297186B2/en active Active
- 2020-11-27 JP JP2022531434A patent/JP7808032B2/ja active Active
-
2022
- 2022-05-10 ZA ZA2022/05149A patent/ZA202205149B/en unknown
- 2022-05-26 SA SA522432749A patent/SA522432749B1/ar unknown
-
2025
- 2025-05-06 US US19/200,279 patent/US20250333395A1/en active Pending
- 2025-07-10 JP JP2025116497A patent/JP2025163046A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SA522432749B1 (ar) | 2025-05-12 |
| AU2020394531B2 (en) | 2026-06-25 |
| US12297186B2 (en) | 2025-05-13 |
| JP7808032B2 (ja) | 2026-01-28 |
| CN114787145B (zh) | 2024-03-26 |
| KR20220107180A (ko) | 2022-08-02 |
| WO2021105317A1 (en) | 2021-06-03 |
| IL293388B1 (en) | 2025-12-01 |
| EP4065572A1 (en) | 2022-10-05 |
| IL293388B2 (en) | 2026-04-01 |
| BR112022010251A2 (pt) | 2022-09-06 |
| US20250333395A1 (en) | 2025-10-30 |
| JP2025163046A (ja) | 2025-10-28 |
| AU2020394531A1 (en) | 2022-06-09 |
| AR120578A1 (es) | 2022-02-23 |
| US20230025933A1 (en) | 2023-01-26 |
| JP2023504795A (ja) | 2023-02-07 |
| PH12022551177A1 (en) | 2024-02-05 |
| ZA202205149B (en) | 2025-06-25 |
| MX2022005843A (es) | 2022-07-19 |
| IL293388A (en) | 2022-07-01 |
| CA3160963A1 (en) | 2021-06-03 |
| CN114787145A (zh) | 2022-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20252775A1 (es) | Compuestos de pirido[4,3-d]pirimidina | |
| ES2525429T3 (es) | Inhibidores de la proteína tirosina fosfatasa humana y métodos de uso | |
| RU2011121567A (ru) | Изоиндолиновые соединения для применения при лечении рака | |
| AU2021231064B2 (en) | Treatment of pain and vasoconstriction | |
| JP2017523225A5 (cg-RX-API-DMAC7.html) | ||
| JP2010532383A5 (cg-RX-API-DMAC7.html) | ||
| MX2024015961A (es) | Compuesto de 3,4-dihidroquinolin-2 (1h)-ona | |
| JP2015535247A5 (cg-RX-API-DMAC7.html) | ||
| JP2012522805A5 (cg-RX-API-DMAC7.html) | ||
| PE20232046A1 (es) | N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)-quinolin-4-carboxamidas | |
| JP2023504795A5 (cg-RX-API-DMAC7.html) | ||
| US11690848B2 (en) | Alkoxy pyrazoles as soluble guanylate cyclase activators | |
| US10485786B2 (en) | Pharmaceutical composition for preventing or treating macular degeneration | |
| CO2024002712A2 (es) | Azálidos inmunomoduladores | |
| ES2573295T3 (es) | Combinaciones farmacéuticas que comprenden un inhibidor de Hsp90 derivado de isoxazol y el inhibidor de HER2 trastuzumab | |
| WO2022034909A1 (ja) | セペタプロストを含有する医薬製剤 | |
| US20120213867A1 (en) | Raf inhibitors for the treatment of thyroid cancer | |
| AU2020264969B2 (en) | Tie-2 activators targeting the schlemm's canal | |
| RU2019104928A (ru) | Производное индола, используемое в качестве ингибитора CRTH2 | |
| JP2014521647A5 (cg-RX-API-DMAC7.html) | ||
| WO2019124487A1 (ja) | オミデネパグの組合せ | |
| NZ739077B2 (en) | Il-8 inhibitors for use in the treatment of certain urological disorders | |
| RU2020140357A (ru) | Новые хинолиновые производные | |
| EA041729B1 (ru) | Соединение, композиция и применение для лечения гиперурикемии или подагры |